Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Sunday's Question of the Day

In June, 2010, shortly after the end of the current fiscal year, the BoD awarded the two highest compensated directors and the interim CEO additional options at 10 cents.

In your opinion, what justification did the BoD use when granting these new options in addition to their "regular" compensation:

A. enhancement of shareholder value

B. increased revenue and profits

C. successful M&A program

D. substantial licensing deals

E. based on BoD qualification and experience

F. they could take them and shareholders could do nothing about it

G. greed

Share
New Message
Please login to post a reply